GLP-1 Receptor Agonists Show Promise as Adjuncts to Cardiac Rehabilitation in Obese HFpEF Patients
Background
Despite advances, Heart Failure (HF), especially Heart Failure with preserved Ejection Fraction (HFpEF), remains a significant challenge with high morbidity and mortality. Current pharmacological and rehabilitative care often falls short, particularly in obese patients where obesity plays a central role in HFpEF pathophysiology. There's a critical need for adjunct therapies that can address the complex cardiometabolic dysfunction in this population, beyond traditional glucose-lowering effects, to improve outcomes and enhance the efficacy of cardiac rehabilitation.
Study Design
This comprehensive review synthesized current literature on glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the context of heart failure (HF), focusing on their mechanisms and clinical evidence. It specifically examined the role of GLP-1RAs as potential adjuncts to cardiac rehabilitation (CR), particularly in obese patients with HFpEF. The review analyzed existing data on how GLP-1RAs interact with cardiometabolic pathways and their impact on HFpEF-associated abnormalities, identifying gaps in understanding regarding synergistic effects with CR.
Results
GLP-1RAs confer significant cardiometabolic benefits beyond glucose-lowering, proving particularly effective in obese patients with HFpEF. These benefits include promoting weight loss, reducing insulin resistance, mitigating leptin signaling, and improving hemodynamic and metabolic abnormalities associated with HFpEF. Evidence suggests GLP-1RA benefits are phenotype-specific, being more pronounced in HFpEF than in HFrEF. Current guidelines already recommend GLP-1RAs for patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or high CV risk, with recent updates acknowledging their potential in HFpEF and obesity. While cardiac rehabilitation (CR) is crucial, caloric restriction and aerobic exercise alone are often insufficient in obese HFpEF patients. The most frequent adverse effects of GLP-1RAs are gastrointestinal events, generally mild to moderate, but can lead to discontinuation in some patients.
GLP-1RAs promote weight loss, reduce insulin resistance, and improve hemodynamic and metabolic abnormalities in obese HFpEF patients.
Key Findings
- GLP-1RAs offer cardiometabolic benefits, particularly for obese patients with Heart Failure with preserved Ejection Fraction (HFpEF).
- Benefits include weight loss, reduced insulin resistance, and improved hemodynamic and metabolic abnormalities in HFpEF.
- Evidence suggests GLP-1RA efficacy is phenotype-specific, more pronounced in HFpEF than in HFrEF.
- GLP-1RAs could serve as effective adjuncts to cardiac rehabilitation, especially where traditional interventions are insufficient.
- Gastrointestinal events are the most common adverse effects, generally mild but can lead to treatment discontinuation.
Why It Matters
GLP-1RAs represent a promising adjunctive therapy to enhance cardiac rehabilitation, especially for patients with obesity-related HFpEF. Their ability to induce weight loss, improve insulin sensitivity, and normalize metabolic parameters directly addresses key pathophysiological drivers of HFpEF that traditional CR often struggles to fully resolve. This suggests that combining GLP-1RAs with CR could lead to more profound and sustained improvements in patient outcomes. While current clinical guidelines are evolving, further research is needed to define optimal dosing and timing for synergistic effects with CR, and to clarify long-term safety and efficacy in broader HF populations beyond obese HFpEF phenotypes.
glp-1ra
heart-failure
hfpef
obesity
cardiac-rehabilitation
cardiometabolic